2024
546VP Deep immunoprofiling in inclusion body myositis and trajectory analysis
Roy B, DiStasio M, Hackbarth R, Bahrassa F, Joo D, Pham M, O'Connor K. 546VP Deep immunoprofiling in inclusion body myositis and trajectory analysis. Neuromuscular Disorders 2024, 43: 104441.137. DOI: 10.1016/j.nmd.2024.07.146.Peer-Reviewed Original ResearchCytotoxic T cellsInclusion body myositis patientsInclusion body myositisIdiopathic inflammatory myopathiesT cell repertoireT cellsB cell repertoireHealthy controlsB cellsExpression of cytotoxic markersIBM pathogenesisSpatial transcriptomic analysisAnalysis of peripheral blood mononuclear cellsPeripheral blood mononuclear cellsCD8 T cellsDifferentiation of cytotoxic T cellsT cell differentiation pathwayMemory B cellsBlood mononuclear cellsAbundant plasma cellsAsymmetric muscle weaknessInflammatory myopathiesCytotoxic markersTranscriptome analysis of muscle tissuesPlasma cellsAssessing Effects of Intrathecal Nicardipine on Cerebral Autoregulation and Cortical Activity in Aneurysmal Subarachnoid Hemorrhage (P10-5.019)
Jayasundara S, Kim J, Choi R, Rapuano A, Barnes E, Parasram M, Moura M, Uppal P, Chen Y, Top I, Olexa M, Maarek R, Yan J, Beekman R, Magid-Bernstein J, Hebert R, Bahrassa F, Matouk C, Sheth K, Gilmore E, Petersen N. Assessing Effects of Intrathecal Nicardipine on Cerebral Autoregulation and Cortical Activity in Aneurysmal Subarachnoid Hemorrhage (P10-5.019). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000206285.Peer-Reviewed Original Research
2020
Predictors of Extended Length of Stay following Treatment of Unruptured Adult Cerebral Aneurysms
Koo A, Elsamadicy A, Lin I, David W, Freedman I, Sujijantarat N, Cord B, Hebert R, Bahrassa F, Malhotra A, Matouk C. Predictors of Extended Length of Stay following Treatment of Unruptured Adult Cerebral Aneurysms. Neurosurgery 2020, 67 DOI: 10.1093/neuros/nyaa447_147.Peer-Reviewed Original ResearchFactor Xa Inhibitor-Related Intracranial Hemorrhage
Panos N, Cook A, John S, Jones G, Kelly H, Choi R, Kalaria N, Rosini J, Jones M, Rehman M, Ross P, Motley B, Delibert S, George B, Andrews C, Neyens R, Martin R, Schomer K, Armahizer M, Pajoumand M, May C, Smetana K, Strohm T, Hamm C, Jakubowski L, Keegan S, Srinivasan V, Burdick C, Martinez O, Bahrassa F, May S, Sowers K, Lin E, Rohaley D, Mackey J, Wetmore L, Frick C, Thatikunta M, Urben L, Ammar A, Owusu K, Nguyen K, Erdman M, Gilbert B, DeMott J, Peksa G, Tobias P, Da Silva I, Mahmoud L, Sheahan B, Gennaro A, Pizzi M, Brophy G, Rivet D, Strein M, Arandela K, Hellerslia V, Caylor M. Factor Xa Inhibitor-Related Intracranial Hemorrhage. Circulation 2020, 141: 1681-1689. PMID: 32264698, DOI: 10.1161/circulationaha.120.045769.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood Coagulation FactorsFactor Xa InhibitorsFemaleHematoma, SubduralHemostasisHemostaticsHospital MortalityHumansIntracranial ThrombosisLength of StayMaleMiddle AgedPyrazolesPyridonesRetrospective StudiesRisk FactorsRivaroxabanSubarachnoid HemorrhageTime FactorsTreatment OutcomeUnited StatesConceptsProthrombin complex concentrateInfusion-related reactionsIntracranial hemorrhageFactor Xa inhibitorsPCC administrationGood hemostasisHospital mortalityThrombotic eventsXa inhibitorsEfficacy of PCCHemostatic efficacyMedian intensive care unitAdministration of PCCOral factor Xa inhibitorsPrimary efficacy outcomeThrombotic event occurrencesObservational cohort studyPercentage of patientsIntensive care unitLength of stayPrimary analysis groupHospital lengthEfficacy outcomesHospital dischargeSecondary outcomes